BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31711435)

  • 1. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
    Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
    BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
    Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
    Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
    J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
    Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
    Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution, and correlation with cervical cytology.
    Ali MAM; Bedair RN; Abd El Atti RM
    Cancer Cytopathol; 2019 Sep; 127(9):567-577. PubMed ID: 31390155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
    Miller RA; Mody DR; Tams KC; Thrall MJ
    Arch Pathol Lab Med; 2015 Nov; 139(11):1431-6. PubMed ID: 25951104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany.
    Kovács K; Varnai AD; Bollmann M; Bankfalvi A; Szendy M; Speich N; Schmitt C; Pajor L; Bollmann R
    J Med Virol; 2008 Oct; 80(10):1814-23. PubMed ID: 18712836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
    Cibas ES; Hong X; Crum CP; Feldman S
    Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Holt HK; Zhang L; Zhao FH; Hu SY; Zhao XL; Zhang X; Pan QJ; Zhang WH; Smith JS; Qiao YL
    Int J Cancer; 2017 Feb; 140(3):544-554. PubMed ID: 27727464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
    Horn J; Denecke A; Luyten A; Rothe B; Reinecke-Lüthge A; Mikolajczyk R; Petry KU
    Br J Cancer; 2019 May; 120(10):1015-1022. PubMed ID: 30988395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
    Li Z; Austin RM; Guo M; Zhao C
    Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
    Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
    Wang HY; Kim H; Park KH
    Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
    Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
    J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.